> Company >
• PLS-D5000 Dog DNA Cancer Immunotherapy INAD filed
• PLS-D1000 Dog DNA Immune Modulator
INAD filed
• LifeTide®SW5, obtained Marketing
Approval in Korea
• PLS-FMD 3 Serotype(A∙O ∙Asia1) DNA Vaccine, S selected for Small & Middle Sized Enterprise Admiration Project
• PLS-D5000, selected for IP-R&D Project
• PLS-D5000, selected for Korean Government Project
• R&D Center moved to Catholic University of Korea in Seoul
• PLS-D5000 Dog DNA Cancer Immunotherapy
R&D
• PLS-D1000 Dog DNA Immune Modulator R&D
• LifeTide®SW5, Applied for Marketing Approval in Korea
• Listed in KONEX
• Acquired 100% of Inovio's animal
subsidiary asset
• Founded in Seoul, Korea
